Myeloma Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Myeloma program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Myeloma Program Today - Breaking & Trending Today

Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant

UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers. ....

United States , Francisco Thomasg Martin , California Institute Of Regenerative Medicine , Cancer Immunology Immunotherapy Program , Helen Diller Family Comprehensive Cancer Center , Myeloma Program , California Institute , Regenerative Medicine , Refractory Multiple Myeloma , Diller Family Comprehensive Cancer Center , Cancer Immunology , Ucsf Helen Diller Family Comprehensive Cancer Center , Thomasg Martin , California Institute Of Regenerative Medicine , Cart Cell Therapy For Multiple Myeloma ,

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma. ....

United States , San Francisco , Talquetamab Talvey , Helen Diller Family Comprehensive Cancer Center , American Society Of Hematology Annual Meeting , University Of California , Myeloma Program , Hematology Annual , Ajai Chari , Multiple Myeloma Program , Diller Family Comprehensive Cancer ,

Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.
....

United States , San Francisco , Myeloma Program , University Of California , Helen Diller Family Comprehensive Cancer Center , Findings From , Refractory Multiple , Multiple Myeloma Program , Diller Family Comprehensive Cancer Center , Ash Annual Meeting And Exposition , Onclive Tv , Multiple Myeloma ,

New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ Johnson & Johnson announced today an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ (talquetamab-tgvs) in patients with relapsed or. ....

United States , San Francisco , Christie Corbett , Satu Glawe , Christoph Heuck , American Society Of Hematology , None Of Janssen Research Development , Hematology Clinical Development , European Commission , Janssen Research Development , Eastern Cooperative Oncology Group , Janssen Biotech Inc , University Of California , Myeloma Program , International Myeloma Working Group , Exchange Commission , Annual Meeting , Ajai Chari , Multiple Myeloma Program , Clinical Medicine , Pivotal Phase , Highlight Reported Continued Efficacy , Reduced Intensity , Vice President , Johnson Innovative , Independent Review Committee ,

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma. ....

San Francisco , United States , Talquetamab Talvey , Helen Diller Family Comprehensive Cancer Center , Myeloma Program , University Of California , Ajai Chari , Multiple Myeloma Program , Diller Family Comprehensive Cancer , Gprc5d Cd3 Bispecific Antibody , Phase 1 2 Monumental Studies , Relapsed Refractory Multiple Myeloma , 2023 Ash Annual Meeting , Adverse Effects ,